BioAdaptives Announces New Trial Showing PrimiCell® Improved Muscle Repair by over 56%

LAS VEGAS, Dec. 7, 2014 /PRNewswire/ -- BioAdaptives, Inc. (BDPT) announced results of the recently completed in vivo trial showing the efficacy of its PrimiCell^® product on muscle repair.

In the study mice were put into groups, PrimiCell^® and the control group. The PrimiCell^® group was given PrimiCell^® for seven days prior to the treatment. Both groups were injected with cardiotoxin in the leg to cause muscle damage. At day one after the injection, day five, and day seven, test subjects from each group were analyzed to determine lesion size, inflammation, necrosis, and overall improvement. Results on day seven showed the PrimiCell^® group had overall improvement greater than 56% better than the control group. The results are shown in the graph below.

BioAdaptives, Inc. Chairman and CEO, Barry Epling said, "The results partially explain the dramatic improvement we are seeing with PrimiCell^® in humans and with animals using Equine Regen™ and Canine Regen™ which are the targeted animal formulations derived from the research and clinical trials completed on PrimiCell^®."

Epling further stated, "BioAdaptives remains committed to further studies and observations of humans, performance horses, and companion animals."

About BioAdaptives, Inc.

BioAdaptives, Inc. is a fully-reporting, public company trading on the OTC Bulletin Board under the symbol BDPT. The company is engaged in research and development in science-based nutraceutical products for human and animal consumption. The company's focus, in conjunction with Ferris Holding, Inc., is to source high quality, unique, raw material worldwide and develop science-based products to improve health and wellness in both humans and animals. BioAdaptives, Inc., has developed a proprietary method that is a non-intrusive bioelectromagnetic device for improving individual ingredients, food, beverages, and wellness.

SAFE HARBOR ACT

Forward-Looking Statements: This release contains statements that constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements appear in a number of places in this release and include all statements that are not statements of historical fact regarding the intent, belief or current expectations of BioAdaptives, Inc. and its directors or its officers with respect to, among other things: (i) financing plans; (ii) trends affecting its financial condition or results of operations; (iii) growth strategy and operating strategy. The words "may," "would," "will," "expect," "estimate," "can," "believe," "potential" and similar expressions and variations thereof are intended to identify forward-looking statements. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond BioAdaptives, Inc.'s ability to control, and actual results may differ materially from those projected in the forward-looking statements as a result of various factors. More information about the potential factors that could affect the business and financial results is and will be included in BioAdaptives, Inc.'s filings with the Securities and Exchange Commission.

Photo - http://photos.prnewswire.com/prnh/20141208/162778-INFO

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/bioadaptives-announces-new-trial-showing-primicell-improved-muscle-repair-by-over-56-300005918.html

SOURCE BioAdaptives, Inc.

Copyright 2014 PR Newswire